Calico(CRC)

LONG BEACH, CABiotechnology2 H-1B visas (FY2023)

Focus: Calico is a publicly-traded biotechnology company headquartered in Long Beach, CA, specializing in aging treatments with a diversified pipeline across oncology, cardiovascular, and infectious disease indications.

Oncology Cardiovascular Infectious Diseases Unknown

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Calico

AI assessmentNot Hiring

No open roles listed right now. Follow Calico to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$2.8B

Pipeline & Clinical Trials

DRUG: ABBV-CLS-484

Advanced Solid Tumor Cancer

N/A

Clinical Trials (1)

NCT06188975Expanded Access to ABBV-CLS-484

N/A

Help build intelligence for Calico

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with $2.8B revenue (FY2025) and $564M net income provides financial stability and career visibility
Diverse pipeline of 22 programs across multiple therapeutic areas including oncology and neurodegenerative disease creates breadth of opportunity
Perfect H1B track record (2 approvals, 0 denials in 2023) signals commitment to international talent recruitment

Watch Out For

Only 1 active job opening suggests minimal near-term hiring and limited career entry points
Heavily early-stage pipeline (9 Phase 1 programs vs. only 1 Phase 3) indicates extended timelines to clinical validation and commercial upside

Generated by Claude from Calico's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Endovascular Aneurysm Repair with Physician Modified Endograft

Juxtarenal Abdominal Aortic Aneurysm

N/A

iLUX Treatment System

Meibomian Gland Dysfunction

N/A

Clinical Trials (1)

NCT06278584iLux Treatment for Meibomian Gland Dysfunction

N/A

Intervention with Consolidated Cysteine

COVID-19 (SARS-CoV-2 Infection)

N/A

Clinical Trials (1)

NCT07184398Use of a Cysteine-rich Whey Protein Isolate in Post COVID-19 Cognitive Impairment

N/A

Pain neuroscience education

Cancer Pain

N/A

Clinical Trials (1)

NCT05581784Effectiveness of a Pain Neuroscience Education Program in Adults With Cancer Pain

N/A

AI-Guided Exercise and Pain Neuroscience Education

Fibromyalgia

N/A

Clinical Trials (1)

NCT06672419Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA)

N/A

ABBV-CLS-579

Advanced Solid Tumors Cancer

PHASE_1

Clinical Trials (1)

NCT04417465First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Phase 1

ABBV-CLS-484

Advanced Solid Tumor Cancer

PHASE_1

Clinical Trials (1)

NCT04777994Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Phase 1

ABBV-CLS-7262

Healthy

PHASE_1

Clinical Trials (1)

NCT05763459A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

Phase 1

Fosigotifator

ALS

PHASE_1

Clinical Trials (1)

NCT04948645A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

Phase 1

ABBV-CLS-7262

Healthy

PHASE_1

Clinical Trials (1)

NCT06310876A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

Phase 1

[14C] ABBV-CLS-7262

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT06425003Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

Phase 1

ABBV-CLS-7262

Healthy

PHASE_1

Clinical Trials (1)

NCT06145607A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

Phase 1

ABBV-CLS-616

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT06698926A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

Phase 1

Fosigotifator

Vanishing White Matter Disease

PHASE_1_2

Clinical Trials (1)

NCT05757141An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

Phase 1/2

CPL-01

Inguinal Herniorrhaphy

PHASE_2

Clinical Trials (1)

NCT05080959A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

Phase 2

ABBV-CLS-628

Autosomal Dominant Polycystic Kidney Disease

PHASE_2

Clinical Trials (1)

NCT06902558A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 2

Analgesic Non Narcotic

Hallux Valgus and Bunion

PHASE_2

Clinical Trials (1)

NCT05411861Post-Operative Pain and Opioid Reduction Trial After Bunionectomy

Phase 2

CPL-01

Abdominoplasty

PHASE_2

Clinical Trials (1)

NCT04182880Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

Phase 2

ABBV-CLS-7262 Dose 1

Amyotrophic Lateral Sclerosis

PHASE_2_3

Clinical Trials (1)

NCT05740813HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

Phase 2/3

local anaesthetic injection

Hernia, Inguinal

PHASE_3

Clinical Trials (1)

NCT05813847Herniorrhaphy for Postoperative Pain

Phase 3

Local anesthetic injection of CPL-01

Bunion

PHASE_3

Clinical Trials (1)

NCT05831449CPL-01 in the Management of Postoperative Pain After Bunionectomy

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 21 clinical trials

Top TAs: Oncology, Neurology, Nephrology

H-1B (2023): 2 approvals

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

3 pipeline

Neurology

2 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$2.8B3%

Net Income

$564M

Cash

$372M

Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo